SAT0203 THE CORRELATION BETWEEN THE SERUM 1,25(OH)2D3 LEVEL AND CLINICAL DATA OF PATIENTS WITH PRIMARY SJOGREN’S SYNDROME

Background: The role of vitamin D in regulating immune function in autoimmune diseases has been extensively studied. While there is less research on vitamin D in Sjogren’s syndrome. This study will explain the relationship between vitamin D and Sjogren’s syndrome. Objectives: To explore the relationship between the serum 1,25(OH)2D3 level and the changes of disease activity in patients with Primary Sjogren’s Syndrome (PSS) [1], and to explore whether supplementation of VD could be a potential therapy for the treatment of PSS. Methods: PSS patients (n=60, according to the 2002 International Classification (Diagnostic) Standard for Sjogren’s Syndrome) were enrolled and health individuals were normal controls. Laboratory examinations were analyzed including that serum levels of 1,25-dihydroxycholecalciferol [1,25(OH)2D3], lymphocytes and CD4+T cell subsets by flow cytometry, urine pH value, ALT, AST, BUN, Cr, IgG, C3, C4, ESR, CRP, serum levels of 1,25(OH)2D3. Physical examination data include Salivary flow rate, secretion of tears, breakup time of tear film (BUT), and labial glands biopsy. Patient‘s disease activity was accord to ESSDAI (EULAR SS disease activity index, 2010) classification. Results: Compared with that in normal controls, the levels of serum VD in patients with PSS was decrease significantly, Z= -7.367, P Conclusion: The level of serum VD in PSS patients was significantly lower than that in normal controls, which was negatively correlated to secretion of tears, IgG, the absolute number of B, Th1, and Th17, the percentage of B and Th17, and radios of Th1/Th2 and Th17/Tregs. Raising serum VD levels by supplementation of VD, may be a potential Therapy for Sjogren’s syndrome. References [1] Garcia-Carrasco M, Jimenez-Herrera EA, Galvez-Romero JL, de Lara LV, Mendoza-Pinto C, Etchegaray-Morales I, et al. Vitamin D and Sjogren syndrome. Autoimmun Rev. 2017;16(6):587-93. Results are given as median (P25,P75), patients with PSS 10.2 0(9.00,15.11), healthy people 20.71(15.16,26.41) Z=-7.37 P Disclosure of Interests: None declared